Evaluation of outcomes and cost-effectiveness of implementing next generation human papillomavirus (HPV) vaccination and associated primary HPV-based cervical cancer screening strategies in Australia

对澳大利亚实施下一代人乳头瘤病毒 (HPV) 疫苗接种和相关的基于 HPV 的宫颈癌筛查策略的结果和成本效益的评估

• 批准号: nhmrc : 1065892
• 负责人: A/Pr Sarah Lord
• 金额: $ 46.48万
• 依托单位: NSW Cancer Council
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/evaluation-outcomes-cost-strategies-australia/455204
• 关键词: Evaluation; outcomes; cost; effectiveness; implementing

This project involves using simulation modelling to predict the effect of the next generation human papillomavirus (HPV) vaccine, which will protect against infection with more strains of HPV. The investigators will use large datasets garnered from around the world to inform the assessment of the cost-effectiveness of this new vaccine in Australia and other key countries, and also to assess whether cervical screening will need to change in the future to account for the introduction of the new vaccine.

该项目涉及使用模拟建模来预测下一代人乳头瘤病毒（HPV）疫苗的效果，该疫苗将保护免受更多HPV菌株的感染。研究人员将使用从世界各地收集的大型数据集来评估这种新疫苗在澳大利亚和其他主要国家的成本效益，并评估宫颈筛查是否需要在未来改变以解释新疫苗的引入。